Aptose Biosciences Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
APTO Nasdaq 2836 www.aptose.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aptose Biosciences Inc.

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial - Jan 9th, 2025 9:00 pm
Aptose Announces Positive Decision by Nasdaq Hearings Panel - Dec 19th, 2024 9:05 pm
Aptose Says Tusepetinib Preclinical Data Published in AACR Journal - Dec 12th, 2024 4:33 pm
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax - Dec 12th, 2024 3:15 pm
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - Dec 9th, 2024 5:00 pm
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials - Dec 3rd, 2024 12:30 pm
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - Nov 25th, 2024 9:15 pm
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results - Nov 22nd, 2024 9:00 pm
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering - Nov 22nd, 2024 1:00 pm
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy - Nov 20th, 2024 12:30 pm
Aptose Reports Results for the Third Quarter 2024 - Nov 8th, 2024 9:01 pm
Aptose Announces Results from Special Meeting of Shareholders - Sep 5th, 2024 8:15 pm
Aptose Biosciences secures funds for AML treatment development - Sep 2nd, 2024 8:12 am
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib - Aug 30th, 2024 8:30 pm
Aptose Announces Adjournment of its Special Meeting of Shareholders - Aug 15th, 2024 8:30 pm
Aptose Biosciences: Q2 Earnings Snapshot - Aug 8th, 2024 10:07 pm
Aptose Reports Results for the Second Quarter 2024 - Aug 8th, 2024 9:06 pm
Aptose Announces Receipt of Deficiency Notice from Nasdaq - Jul 19th, 2024 9:00 pm
Aptose Announces Results from Annual and Special Meeting of Shareholders - Jun 18th, 2024 9:30 pm
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress - Jun 14th, 2024 11:30 am